Navigation Links
AACR congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award
Date:10/21/2010

PHILADELPHIA The American Association for Cancer Research expresses its congratulations to and appreciation of William S. Dalton, M.D., Ph.D., who will receive the 2010 Leadership in Personalized Medicine Award from the Personalized Medicine Coalition (PMC).

Dalton, who has been a distinguished member of the AACR for more than 20 years, will receive the award from the PMC at the Harvard Personalized Medicine Conference on Nov. 17. According to the PMC, he is recognized for "his pioneering work putting the concepts of personalized medicine into practice for the benefit of patients."

Dalton is the chief executive officer of the H. Lee Moffitt Cancer Center in Tampa, Fla. He also serves as chair of the AACR's Science Policy and Legislative Affairs Committee.

"This is a wonderful and fitting honor for Dr. Dalton, who is at the forefront of personalized medicine and whose work has benefitted countless cancer patients," said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. "Moreover, Dr. Dalton's contributions extend beyond the lab and clinic to the halls of Congress. As chair of the AACR's Science Policy and Legislative Affairs Committee, he convenes the committee that guides the AACR's policy efforts. Dr. Dalton is a leader who is impacting the field on many levels, and we celebrate his achievement."

Dalton received his doctoral degree in toxicology and medical life sciences and his medical degree from Indiana University. He completed his internship in internal medicine at Indiana University, his residency in medicine at the University of Arizona in Tucson and his fellowships in oncology and clinical pharmacology at the University of Arizona. He is board certified in internal medicine and medical oncology and is an expert in multiple myeloma.

The PMC Award recognizes an individual whose contributions in science, business and/or policy have helped advance the frontiers of personalized medicine
'/>"/>

Contact: Rachael Cullins
Rachael.Cullins@aacr.org
202-898-0668
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. GSA congratulates 2008 award winners
2. The American Association for Cancer Research congratulates Margaret Hamburg, M.D.
3. Elsevier congratulates Royal Australian Chemical Institutes Athel Beckwith Lectureship winner
4. The AACR congratulates its members elected to the Institute of Medicine
5. 2 genes influence social behavior, visual-spatial performance in people with Williams syndrome
6. AIUM presents 2009 William J. Fry Memorial Lecture award
7. Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVaults Board of Directors
8. University of Cincinnatis William Vanooij earns first Ohio Patent Award from Ohio Academy of Science
9. Christopher Marley and James McWilliams to give plenary speeches at Entomology 2010
10. Gender biases in leadership selection during competitions within and between groups
11. PNNL leadership in carbon sequestration featured at international conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nxt-ID, Inc. (OTCQB: NXTD), a biometric ... announced today that its shares of common stock and ... in its proposed underwritten public offering of common stock ... Nasdaq Capital Market, subject to closing of its proposed ... and will trade under the symbol "NXTD" and "NXTDW," ...
(Date:8/21/2014)... a previously unknown process for harvesting energy and producing ... Penn State University scientist has discovered. The discovery lays ... growth, harvesting energy from the Sun, and understanding dense ... other lakes worldwide. A paper describing the discovery will ... of the journal Science on 21 August ...
(Date:8/21/2014)... easy to ignore, but they are the ultimate source ... Humans are increasingly dependent on algae, too, to suck ... it to the bottom of the ocean. Now, by ... researchers have evidence showing that viruses infecting those algae ... even when all else stays essentially the same, and ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
... (hNoV), also known as the winter vomiting bug, is one ... virus is highly contagious, causing vomiting and diarrhea, and the ... cure; sufferers have to let the virus run its course ... is frequently associated with outbreaks of hNoV but it remains ...
... The human skin is home to countless microorganisms that we ... Our invisible passengers known as the skin microbiome - ... immune system, protecting us from pathogens, and mediating skin disorders. ... is transmitted between players in a contact sport, using roller ...
... in French . Researchers at the University ... discovered a new mechanism that allows some cells in our body ... by Roman soldiers depicted in the Asterix series. Collective cell migration ... but it is also used by cancerous cells to disseminate efficiently ...
Cached Biology News:What impact does a day of roller derby have on our skin microbiome? 2Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow 2
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Helix BioPharma Corp. (TSX, FSE: "HBP") announced ... in Germany to initiate its planned Phase II ... with low-grade cervical lesions.The clinical study was designed, ... on the absorption and elimination profile of Topical ...
... Percent of Outstanding Indevus Shares Have Been Accepted ... Pharmaceuticals (Nasdaq: ENDP ) announced today ... time, on March 13, 2009, approximately 71,008,964 shares ... were validly tendered and accepted for purchase in ...
... PortfolioNEW YORK, March 16 Samtheo Biopharma LLC ... subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, ... that selectively inhibits the activation of all three ... pathway has been found to play an important ...
Cached Biology Technology:Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 2Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 3Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 4Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 5Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 2Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 3Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Immunogen: ... acids 22-37 SGHKSEEKREKMKRTL Antigen ... G-protein signalling; Antigen Subfamily: ... G-protein signalling Recommended Storage: ...
Biology Products: